Pitavastatin: A new HMG-CoA reductase inhibitor

Annals of Pharmacotherapy

Volumn 44, Issue 3, 2010, Pages 507-514

  Wensel, Terri M ^a   Waldrop, Bruce A ^a   Wensel, Brian ^b  

^a SAMFORD UNIVERSITY   (United States)

^b DCH Regional Medical Center   (United States)

Author keywords

HMG CoA reductase inhibitor; Hypercholesterolemia; NK 104; Pitavastatin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CREATINE KINASE; CYTOCHROME P450; ERYTHROMYCIN; GAMMA GLUTAMYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; LOPINAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORGANIC ANION TRANSPORTER 2; PITAVASTATIN; PRAVASTATIN; RIFAMPICIN; RITONAVIR; ROSUVASTATIN; SIMVASTATIN;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; CLINICAL TRIAL; CONSTIPATION; CREATINE KINASE BLOOD LEVEL; DIZZINESS; DNA POLYMORPHISM; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; EDEMA; FATIGUE; FOOD AND DRUG ADMINISTRATION; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; INDIGESTION; INSOMNIA; LOOSE FECES; MEDICAL LITERATURE; MEDLINE; MYALGIA; MYOPATHY; NAUSEA; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT; TREATMENT DURATION; XEROSTOMIA;

CHOLESTEROL, LDL; DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77749329736     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M624     Document Type: Review

References (27)

1. Product information. Livalo (pitavastatin). Montgomery, AL: Kowa Pharmaceuticals America, Inc., July 2009.
2. Igel M, Sudhop T, von Bergmann K. Pharmacology of 3-hydroxy-3- methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin. J Clin Pharmacol 2002;42:835- 45.
3. FDA/CDER resources page. Food and Drug Administration. www.fda. gov/cder/approval/index.him (accessed 2009 Dec 4).
4. Mukhtar RY, Reid J, Reckless JP. Pitavastatin. Int J Clin Pract 2005;59:239-52.
5. Product information. Mevacor (lovastatin). Whitehouse Station, NJ: Merck & Co., Inc., September 2008.
6. Product information. Zocor (simvastatin). Whitehouse Station, NJ: Merck & Co., Inc., June 2008.
7. Product information. Pravachol (pravastatin). Princeton, NJ: Bristol-Myers Squibb Co., February 2007.
8. Product information. Lipitor (atorvastatin). New York, NY: Pfizer Inc., June 2009.
9. Product information. Lescol, Lescol XL (fluvastatin). East Hanover, NJ: Novartis Pharmaceuticals Corp., October 2006.
10. Product information. Crestor (rosuvastatin). Wilmington, DE: AstraZeneca Pharmaceuticals LP, October 2009.
11. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986;232:34- 47.
12. Chung JY, Cho JY, Yu KS, et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 2005;78:342-50.
13. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 2004;311:139- 46.
14. Kivisto KT, Niemi M. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm Res 2007;24:239- 47.
15. Voora D, Shah SH, Spasojevic I, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009;54:1609-16.
16. Link E, Parish S, Armitage J, et al. SCLO1B1 variants and statin-induced myopathy - a genomewide study. N Engl J Med 2008;359:789-99.
17. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006;112:71-105.
18. Ando H, Tsuruoka S, Yanagihara H, et al. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br J Clin Pharmacol 2005;60:494-7.
19. Saito Y, Yamada N, Teramoto T, et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis 2002;163:373-9.
20. Park S, Kang H, Rim S, et al. A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia. Clin Ther 2005;27:1074-82.
21. Lee SH, Chung N, Kwan J, et al. Comparison of efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia. Clin Ther 2007;29:2365-73.
22. Yokote K, Bujo H, Hanaoka H, et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA) study. Atherosclerosis 2008;201:345-52.
23. Sasaki J, Ikeda Y, Kuribayashi T, et al. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin Ther 2008;30:1089-101.
24. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final Report, 2002. www.nhlbi.nih.gov/ guidelines/cholesterol/atp3full.pdf (accessed 2009 Nov 30).
25. Lexi-comp. www.crlonline.com.ezproxy.samford.edu/crlsql/servlet/crlonline (accessed 2009 Oct 8).
26. Press releases. Kowa Pharmaceuticals America, Inc. www.kowapharma.com/ PressReleases/news080209.htm (accessed 2009 Dec 1).
27. Red Book: pharmacy's fundamental reference. Montvale, NJ: Thomson Healthcare, 2009.